ExploreWatchlistsPricing
  1. US-listed companies
  2. Theravance Biopharma, Inc.
  3. Financials
  4. Cash and cash equivalents

Theravance Biopharma, Inc. (TBPH)

Market cap
$849.63M
P/E ratio
8x
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 2025169+336.52%
Dec 31, 202439-4.33%
Dec 31, 202340-86.50%
Dec 31, 2022299+229.32%
Dec 31, 202191+10.32%
Dec 31, 202082+39.74%
Dec 31, 201959-84.45%
Dec 31, 2018379+325.77%
Dec 31, 201789-74.19%
Dec 31, 2016345+205.85%
Dec 31, 2015113+26.33%
Dec 31, 201489

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat